These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 23852164

  • 1. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P, Scalbert C, Qassemyar A, Kluza J, Ravasi L, Huglo D, Martinot-Duquennoy V, Formstecher P, Marchetti P, Mortier L.
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [Abstract] [Full Text] [Related]

  • 2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [Abstract] [Full Text] [Related]

  • 3. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL, Lopez IE, Desai SR.
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [Abstract] [Full Text] [Related]

  • 5. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.
    Oncotarget; 2016 Dec 13; 7(50):81995-82012. PubMed ID: 27835901
    [Abstract] [Full Text] [Related]

  • 6. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC, Matalka MS.
    Clin Ther; 2012 Jul 13; 34(7):1474-86. PubMed ID: 22742884
    [Abstract] [Full Text] [Related]

  • 7. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ, Evers S, Nayak TK, Bergström M, Su F, Gerrits D, Franssen GM, Boerman OC.
    Contrast Media Mol Imaging; 2015 Jul 13; 10(3):203-10. PubMed ID: 25204436
    [Abstract] [Full Text] [Related]

  • 8. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J.
    Proc Natl Acad Sci U S A; 2017 Jul 18; 114(29):E5930-E5939. PubMed ID: 28684402
    [Abstract] [Full Text] [Related]

  • 9. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
    Babacan T, Türkbeyler IH, Balakan O, Pehlivan Y, Suner A, Kısacık B.
    Int J Rheum Dis; 2017 Mar 18; 20(3):398-401. PubMed ID: 24815010
    [Abstract] [Full Text] [Related]

  • 10. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A, Cohen MS.
    Expert Opin Drug Discov; 2016 Sep 18; 11(9):907-16. PubMed ID: 27327499
    [Abstract] [Full Text] [Related]

  • 11. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J.
    PLoS One; 2013 Sep 18; 8(8):e72692. PubMed ID: 24023633
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 13. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM.
    BioDrugs; 2012 Oct 01; 26(5):325-34. PubMed ID: 22946753
    [Abstract] [Full Text] [Related]

  • 14. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.
    Melanoma Res; 2014 Aug 01; 24(4):415-8. PubMed ID: 24933605
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 01; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 18. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M.
    Ann Pathol; 2013 Dec 01; 33(6):375-85. PubMed ID: 24331719
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM, Lyseng-Williamson KA.
    Am J Clin Dermatol; 2013 Feb 01; 14(1):65-9. PubMed ID: 23329082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.